MapLight Therapeutics, Inc. (MPLT) return on equity (ROE)
Only 1 fiscal year of return on equity is on record here for MapLight Therapeutics, Inc. (MPLT); a history needs at least 3. Figures as of 17 Nov 2026, 22:20 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Return on equity, fiscal 2025
- -35.2%
- Fiscal years on record
- 12025–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.
Not enough data
A history of return on equity needs at least 3 fiscal years; one is on record here for MapLight Therapeutics, Inc.. Nothing is estimated to fill the gap. What is on record is in the table below.
MapLight Therapeutics, Inc. return on equity (ROE), year by year
| Fiscal year | Return on equity | Change | Year ended |
|---|---|---|---|
| 2025 | -35.2% | — |
Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.
How to read it
It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.
MapLight Therapeutics, Inc., figure by figure
- MapLight Therapeutics, Inc. market cap
- MapLight Therapeutics, Inc. revenue
- MapLight Therapeutics, Inc. earnings
- MapLight Therapeutics, Inc. earnings per share (EPS)
- MapLight Therapeutics, Inc. P/E ratio
- MapLight Therapeutics, Inc. P/S ratio
- MapLight Therapeutics, Inc. P/B ratio
- MapLight Therapeutics, Inc. free cash flow
- MapLight Therapeutics, Inc. operating margin
- MapLight Therapeutics, Inc. dividend
- MapLight Therapeutics, Inc. shares outstanding
- MapLight Therapeutics, Inc. total debt
- MapLight Therapeutics, Inc. cash on hand
- MapLight Therapeutics, Inc. total assets
- MapLight Therapeutics, Inc. return on invested capital (ROIC)
MapLight Therapeutics, Inc. (MPLT) overview: price, valuation and scorecard
MapLight Therapeutics, Inc. return on equity (ROE): questions and answers
How is MapLight Therapeutics, Inc.'s return on equity calculated?
Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.
Fiscal years are named for the calendar year they end in.
Learn: return on equity (ROE)
All stocks guides →- Return on invested capital (ROIC) vs ROE and ROA
Return on invested capital (ROIC) is after-tax operating profit divided by the money tied up in the business: debt plus equity, less cash. A company earning $15 million after tax on $100 million of invested capital has a 15% ROIC. Unlike return on equity, it does not rise just because a company borrows more.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “MapLight Therapeutics, Inc. (MPLT) return on equity (ROE)”, data as of 17 November 2026. https://funkfolio.com/stock/MPLT/roe
Underlying data: the company's filings with the SEC and Yahoo Finance.